• No notifications yet.
  • Sign Out
logo image
  • logo image
Registered User? Login

Access to the community is available for registered attendees only. If you have already registered - please join using the link below. 

To register for the event please follow the 'register now' button and summit your details. Please contact ftlive@ft.com with any questions.

Forgot Password?
Sign Up
loader image
New User? Sign Up

Access to the community is available for registered attendees only. If you have already registered - please join using the link below. 

To register for the event please follow the 'register now' button and summit your details. Please contact ftlive@ft.com with any questions.

Forgot Password?
Login
loader image
    Innovative Clinical Research Strategies logo

    Innovative Clinical Research Strategies

    FT DIGITAL DIALOGUES | ​Building resilience in pharma R&D by decentralising and digitising
    ON-DEMAND VIDEO NOW AVAILABLE
    VIEW ON-DEMAND NOW

    IN PARTNERSHIP WITH


    This FT Digital Dialogue on Innovative Clinical Research Strategies, organised in partnership with ICON plc, discussed how to design and run more resilient trials in an uncertain world, where the need to decentralise is driving investment in new technology solutions and changing the pharma R&D landscape.

    Read the full overview

    SPEAKERS

    speaker image
    HK
    Hannah Kuchler
    US Pharma and Biotech Correspondent
    Financial Times
    speaker image
    MI
    Melanie Ivarsson
    Chief Development Officer
    Moderna
    speaker image
    CK
    Christoph Koenen
    EVP-Chief Medical Oficer
    Otsuka
    speaker image
    EM
    E.B. McLindon
    Senior Vice President, Patient, Site & Decentralised Solutions
    ICON plc
    speaker image
    AT
    Ann Taylor
    Chief Medical Officer,
    AstraZeneca
    image placeholder
    AC
    Anthony Costello
    President, Patient Cloud and SVP
    Medidata

    KEY TALKING POINTS

    How is trial design evolving in terms of data collection, safety reporting, tracking and other processes? 


    What are some of the challenges around moving to remote study management and off-site monitoring? 


    What can be done to manage the risks and consequences of trials being suspended and re-started? 


    How could new approaches to clinical trial management affect access to patient populations and how can direct patient support services be improved?


    How can relationships with regulators, patients and other stakeholders evolve to accommodate new processes and solutions? 



    © Financial Times Live

    FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice

    LEGAL

    FAQs
    FT Live Website Terms of Use
    Slavery Statement & Policies
    Contact us
    FT Live Delegate Terms & Conditions
    Privacy policy
    Cookie policy


    SOCIAL

    Instagram
    Twitter
    LinkedIn
    YouTube
    Flickr

Contact the organizer
Contact the organizer